Journal
ONCOIMMUNOLOGY
Volume 6, Issue 8, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2017.1299303
Keywords
Immune biomarkers; Immunotherapy; Melanoma; Predictive factors; Prognostic factors
Categories
Funding
- Institut National du Cancer INCa
- ANR
- Ligue contre le cancer
- Swiss Bridge Foundation
- ISREC Foundation
- LABEX OncoImmunology
- la direction generale de l'offre de soins (DGOS)
- Universite Paris-Sud
- SIRIC SOCRATE [INCa/DGOS/INSERM 6043]
- PACRI network
- PIA2 TORINO-LUMIERE
- Canceropole Ile de France
Ask authors/readers for more resources
Existing clinical, anatomopathological and molecular biomarkers fail to reliably predict the prognosis of cutaneous melanoma. Biomarkers for determining which patients receive adjuvant therapies are needed. The emergence of new technologies and the discovery of new immune populations with different prognostic values allow the immune network in the tumor to be better understood. Importantly, new molecules identified and expressed by immune cells have been shown to reduce the antitumor immune efficacy of therapies, prompting researchers to develop antibodies targeting these so-called immune checkpoints, which have now entered the oncotherapeutic armamentarium.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available